GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:002290017 | Prostate | Tumor | electron transport chain | 76/3246 | 175/18723 | 5.59e-16 | 1.09e-13 | 76 |
GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
GO:007048218 | Prostate | Tumor | response to oxygen levels | 102/3246 | 347/18723 | 1.62e-08 | 5.75e-07 | 102 |
GO:001003819 | Prostate | Tumor | response to metal ion | 107/3246 | 373/18723 | 3.02e-08 | 9.77e-07 | 107 |
GO:003629318 | Prostate | Tumor | response to decreased oxygen levels | 94/3246 | 322/18723 | 8.37e-08 | 2.29e-06 | 94 |
GO:003196017 | Prostate | Tumor | response to corticosteroid | 57/3246 | 167/18723 | 1.11e-07 | 2.94e-06 | 57 |
GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
GO:000166618 | Prostate | Tumor | response to hypoxia | 90/3246 | 307/18723 | 1.27e-07 | 3.28e-06 | 90 |
GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
GO:007124114 | Prostate | Tumor | cellular response to inorganic substance | 66/3246 | 226/18723 | 6.63e-06 | 1.00e-04 | 66 |
GO:007145316 | Prostate | Tumor | cellular response to oxygen levels | 54/3246 | 177/18723 | 1.13e-05 | 1.62e-04 | 54 |
GO:003629416 | Prostate | Tumor | cellular response to decreased oxygen levels | 49/3246 | 161/18723 | 3.02e-05 | 3.62e-04 | 49 |
GO:007124815 | Prostate | Tumor | cellular response to metal ion | 56/3246 | 197/18723 | 7.26e-05 | 7.65e-04 | 56 |
GO:009730518 | Prostate | Tumor | response to alcohol | 68/3246 | 253/18723 | 9.02e-05 | 8.88e-04 | 68 |
GO:007145614 | Prostate | Tumor | cellular response to hypoxia | 45/3246 | 151/18723 | 1.08e-04 | 1.03e-03 | 45 |
GO:000941017 | Prostate | Tumor | response to xenobiotic stimulus | 110/3246 | 462/18723 | 2.13e-04 | 1.84e-03 | 110 |
GO:004668615 | Prostate | Tumor | response to cadmium ion | 24/3246 | 68/18723 | 2.85e-04 | 2.32e-03 | 24 |
GO:007259315 | Prostate | Tumor | reactive oxygen species metabolic process | 63/3246 | 239/18723 | 2.87e-04 | 2.32e-03 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYBB | SNV | Missense_Mutation | | c.942N>C | p.Lys314Asn | p.K314N | P04839 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYBB | SNV | Missense_Mutation | novel | c.1636N>G | p.Leu546Val | p.L546V | P04839 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CYBB | SNV | Missense_Mutation | | c.862N>G | p.Phe288Val | p.F288V | P04839 | protein_coding | tolerated(0.12) | benign(0.426) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CYBB | insertion | Nonsense_Mutation | novel | c.637_638insAATAATCC | p.Val213GlufsTer2 | p.V213Efs*2 | P04839 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYBB | insertion | Frame_Shift_Ins | novel | c.1402_1403insT | p.Arg468MetfsTer18 | p.R468Mfs*18 | P04839 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CYBB | insertion | Frame_Shift_Ins | novel | c.1404_1405insTTAGCCAAATATTTCTCTTTTTACTTCCA | p.Asn469LeufsTer43 | p.N469Lfs*43 | P04839 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CYBB | SNV | Missense_Mutation | novel | c.118N>C | p.Phe40Leu | p.F40L | P04839 | protein_coding | tolerated(0.4) | benign(0.01) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CYBB | SNV | Missense_Mutation | | c.1039N>A | p.Glu347Lys | p.E347K | P04839 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
CYBB | SNV | Missense_Mutation | novel | c.748N>C | p.Glu250Gln | p.E250Q | P04839 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CYBB | SNV | Missense_Mutation | rs781797749 | c.470N>A | p.Arg157Gln | p.R157Q | P04839 | protein_coding | tolerated(0.11) | benign(0.417) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | | APIGENIN | APIGENIN | 23786520 |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894227 | | |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894229 | | |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894225 | | |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | | CHRYSIN | CHRYSIN | 23786520 |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | | LUTEOLIN | LUTEOLIN | 23786520 |
1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894226 | | |